Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)

NCT02766465 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

138

Enrollment

OTHER

Sponsor class

Conditions

Sickle Cell Disease

Interventions

DRUG: Busulfan
DRUG: Fludarabine
DRUG: r-ATG
PROCEDURE: Hematopoietic Cell Transplant
DRUG: Tacrolimus
DRUG: Methotrexate
PROCEDURE: Standard of Care
DRUG: Alemtuzumab
DRUG: Total Body Irradiation (TBI)
DRUG: Sirolimus
DRUG: Melphalan
DRUG: G-CSF

Sponsor

Medical College of Wisconsin

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]